$1.14/ day, billed weekly
Cancel anytime

(Ad-Free, Unlimited access)

NO CREDIT CARD REQUIRED

EXOZ

eXoZymes, Inc. (EXOZ)

$17.39

Delayed price

Profit since last BUY-9.8%

Consider higher Upturn Star rating

BUY since 5 days

BUY Advisory
SELL Advisory (Profit)
SELL Advisory (Loss)

Profit
Loss
Pass (Skip investing)

Time period over

ALL
YEAR
MONTH
WEEK

Upturn Advisory Summary

02/20/2025: EXOZ (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock

Historic Profit -9.8%

Avg. Invested days 5

Today’s Advisory Consider higher Upturn Star rating

Upturn Star Rating

Upturn Advisory Performance

1.0

Stock Returns Performance

1.0

Profits based on simulation

Last Close 02/20/2025

Key Highlights

Company Size Small-Cap Stock	Market Capitalization 185.05M USD	Price to earnings Ratio -	1Y Target Price -
Price to earnings Ratio -	1Y Target Price -
Volume (30-day avg) 31072	Beta -	52 Weeks Range 8.50 - 23.99	Updated Date 02/17/2025
52 Weeks Range 8.50 - 23.99	Updated Date 02/17/2025
Dividends yield (FY) -	Basic EPS (TTM) -0.63

Earnings Date

Report Date -

When -

Estimate -

Actual -

Profitability

Profit Margin -

Operating Margin (TTM) 704833.7%

Management Effectiveness

Return on Assets (TTM) -88.29%

Return on Equity (TTM) -

Valuation

Trailing PE -	Forward PE -	Enterprise Value 189675504	Price to Sales(TTM) -
Enterprise Value 189675504	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -	Shares Outstanding 9528800	Shares Floating 4759538
Shares Outstanding 9528800	Shares Floating 4759538
Percent Insiders 76.34	Percent Institutions 1.21

About eXoZymes, Inc.

Exchange NASDAQ	Headquaters Monrovia, CA, United States
IPO Launch date 2024-11-13	CEO -
Sector Healthcare	Industry Biotechnology	Full time employees 29	Website https://www.invizyne.com
Full time employees 29	Website https://www.invizyne.com

eXoZymes, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. The company was founded in 2014 and is headquartered in Monrovia, California.

https://www.upturn.io

Disclosure Privacy Policy Terms of Use Sitemap Contact Us

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.